OUR MILESTONES | ACHIEVEMENTS
OUR
MILESTONES | ACHIEVEMENTS
MetaPharm Inc. International has contributed to the success of many individual projects. We are particularly proud when this teamwork with our Sponsors leads to achieving product registration – the ultimate goal of clinical development.
Over the years, we have conducted a number of pivotal studies in asthma, epilepsy, pain, and pneumology resulting in Canada marketing authorizations
2019 | Marketing Authorisation
Marketing authorisation granted for a contraceptive pill in the US.
2018 | Technology
new e-signature feature launched.
2017 | Marketing Authorisation
Marketing authorisation granted for an anticonvulsant for peadiadric indication in the US (epilepsy).
2016 | Marketing Authorisation
Marketing authorisation granted for a COMT inhibitor in Europe (Parkinson).
2016 | Technology
Launch of our InSIGHT application, which is a proprietary innovative clinical trial management system (CTMS).
2015 | United States of America
Opening of a new office in Pittsburgh, Pennsylvania, US, start of our expansion with our own staff to the Americas.
2013 | Technology
Launch of Metapharm's application for centralized automated electronic safety reporting (SCORIS).
2013 | Technology
Conception and start of Kaleido Metapharm development – a central portal covering several software solutions: including Safety Reporting (SCORIS) and CTMS (inSIGHT)
2013 | United Kingdom
New office opening in Manchester, UK continuing our expansion in Western Europe.
2013 | Marketing Authorisation
Marketing authorisation granted for an innovative new inhalation device for patients with asthma and/or chronic obstructive pulmonary disease (COPD) in Europe.
2013 | Extension office facilities
Further extension of International’s Mannheim headquarters in Germany.
2013 | Marketing Authorisation
Marketing authorisation granted for an anticonvulsant in the US (epilepsy).